[article] 
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S29-S31

Titre :	Moving the agenda forward: the prevention and management of hepatitis C virus infection among people who inject drugs
Type de document :	Périodique
Auteurs :	J. GREBELY ; P. BRUGGMANN ; M. BACKMUND ; G. J. DORE
Année de publication :	2013
Article en page(s) :	S29-S31
Langues :	Anglais
Mots-clés :	Thésaurus TOXIBASE USAGER ; HEPATITE ; PREVENTION ; INFECTION ; INJECTION ; PRISE EN CHARGE
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	The majority of hepatitis C virus (HCV) occurs among people who inject drugs (PWID), and the burden of HCV-related liver disease is still increasing. HCV treatment is safe and effective among PWID, and international guidelines encourage HCV treatment in this group, but HCV treatment uptake remains low among PWID, mainly due to patient-, practitioner- and systems-related barriers to care. However, strategies have emerged to improve the prevention and management of HCV infection among PWID. To foster the dissemination of knowledge in the field of viral hepatitis among PWID, the International Network on Hepatitis in Substance Users (INHSU) was established. INHSU established the International Symposium on Hepatitis in Substance Users (held every 2 years), focused on the management of viral hepatitis among PWID, specifically HCV infection. The first symposium was held in Zurich, Switzerland, in 2009 and the second was held in Brussels, Belgium, in 2011. The symposium is attended by researchers, practitioners, and community members and includes sessions on the epidemiology and natural history of viral hepatitis, clinical applications of basic science research, management of medical comorbidities and social science- and community-based perspectives. At the meeting in 2011, a panel of international experts was assembled in collaboration with the European Liver Patients Association to develop the first international recommendations for the management of HCV among PWID. This supplement presents original research from the most recent meeting, highlights recent advances in the field, and presents recommendations for the clinical management of HCV infection among PWID. [Extract]
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	24
Affiliation :	The Kirby Institute, University of New South Wales, Sydney, Australia
Lien :	http://dx.doi.org/10.1093/cid/cit264
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74548

[article] Moving the agenda forward: the prevention and management of hepatitis C virus infection among people who inject drugs [Périodique] / J. GREBELY ; P. BRUGGMANN ; M. BACKMUND ; G. J. DORE . - 2013 . - S29-S31.
Langues : Anglais
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S29-S31

Mots-clés :	Thésaurus TOXIBASE USAGER ; HEPATITE ; PREVENTION ; INFECTION ; INJECTION ; PRISE EN CHARGE
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	The majority of hepatitis C virus (HCV) occurs among people who inject drugs (PWID), and the burden of HCV-related liver disease is still increasing. HCV treatment is safe and effective among PWID, and international guidelines encourage HCV treatment in this group, but HCV treatment uptake remains low among PWID, mainly due to patient-, practitioner- and systems-related barriers to care. However, strategies have emerged to improve the prevention and management of HCV infection among PWID. To foster the dissemination of knowledge in the field of viral hepatitis among PWID, the International Network on Hepatitis in Substance Users (INHSU) was established. INHSU established the International Symposium on Hepatitis in Substance Users (held every 2 years), focused on the management of viral hepatitis among PWID, specifically HCV infection. The first symposium was held in Zurich, Switzerland, in 2009 and the second was held in Brussels, Belgium, in 2011. The symposium is attended by researchers, practitioners, and community members and includes sessions on the epidemiology and natural history of viral hepatitis, clinical applications of basic science research, management of medical comorbidities and social science- and community-based perspectives. At the meeting in 2011, a panel of international experts was assembled in collaboration with the European Liver Patients Association to develop the first international recommendations for the management of HCV among PWID. This supplement presents original research from the most recent meeting, highlights recent advances in the field, and presents recommendations for the clinical management of HCV infection among PWID. [Extract]
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	24
Affiliation :	The Kirby Institute, University of New South Wales, Sydney, Australia
Lien :	http://dx.doi.org/10.1093/cid/cit264
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74548

[article] 
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S32-S38

Titre :	Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention
Type de document :	Périodique
Auteurs :	K. PAGE ; M. D. MORRIS ; J. A. HAHN ; L. MAHER ; M. PRINS
Année de publication :	2013
Article en page(s) :	S32-S38
Langues :	Anglais
Mots-clés :	Thésaurus Géographique ETATS-UNIS Thésaurus TOXIBASE HEPATITE ; ADULTE JEUNE ; USAGER ; PREVENTION ; SERINGUE ; REDUCTION DES RISQUES ; INFECTION
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	The hepatitis C virus (HCV) virus epidemic is ongoing in the United States and globally. Incidence rates remain high, especially in young adult injection drug users. New outbreaks of HCV in the United States among young adults, in predominantly suburban and rural areas, have emerged and may be fueling an increase in HCV. This paper discusses some key HCV prevention strategies that to date have not been widely researched or implemented, and wherein future HCV prevention efforts may be focused: (1) reducing sharing of drug preparation equipment; (2) HCV screening, and testing and counseling; (3) risk reduction within injecting relationships; (4) injection cessation and "breaks"; (5) scaled-up needle/syringe distribution, HCV treatment, and vaccines, according to suggestions from mathematical models; and (6) "combination prevention." With ongoing and expanding transmission of HCV, there is little doubt that there is a need for implementing what is in the prevention "toolbox" as well as adding to it. Strong advocacy and resources are needed to overcome challenges to providing the multiple and comprehensive programs that could reduce HCV transmission and associated burden of disease worldwide in people who inject drugs.
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	50
Affiliation :	Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94105, USA
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74549

[article] Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention [Périodique] / K. PAGE ; M. D. MORRIS ; J. A. HAHN ; L. MAHER ; M. PRINS . - 2013 . - S32-S38.
Langues : Anglais
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S32-S38

Mots-clés :	Thésaurus Géographique ETATS-UNIS Thésaurus TOXIBASE HEPATITE ; ADULTE JEUNE ; USAGER ; PREVENTION ; SERINGUE ; REDUCTION DES RISQUES ; INFECTION
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	The hepatitis C virus (HCV) virus epidemic is ongoing in the United States and globally. Incidence rates remain high, especially in young adult injection drug users. New outbreaks of HCV in the United States among young adults, in predominantly suburban and rural areas, have emerged and may be fueling an increase in HCV. This paper discusses some key HCV prevention strategies that to date have not been widely researched or implemented, and wherein future HCV prevention efforts may be focused: (1) reducing sharing of drug preparation equipment; (2) HCV screening, and testing and counseling; (3) risk reduction within injecting relationships; (4) injection cessation and "breaks"; (5) scaled-up needle/syringe distribution, HCV treatment, and vaccines, according to suggestions from mathematical models; and (6) "combination prevention." With ongoing and expanding transmission of HCV, there is little doubt that there is a need for implementing what is in the prevention "toolbox" as well as adding to it. Strong advocacy and resources are needed to overcome challenges to providing the multiple and comprehensive programs that could reduce HCV transmission and associated burden of disease worldwide in people who inject drugs.
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	50
Affiliation :	Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94105, USA
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74549

[article] 
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S39-S45

Titre :	Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy
Type de document :	Périodique
Auteurs :	N. K. MARTIN ; M. HICKMAN ; S. J. HUTCHINSON ; D. J. GOLDBERG ; P. VICKERMAN
Année de publication :	2013
Article en page(s) :	S39-S45
Langues :	Anglais
Mots-clés :	Thésaurus Géographique ROYAUME-UNI Thésaurus TOXIBASE HEPATITE ; INTERVENTION ; USAGER ; REDUCTION DES RISQUES ; MODELE ; TRAITEMENT DE MAINTENANCE ; ECHANGE DE SERINGUES ; ANTIVIRAUX ; PREVALENCE
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	BACKGROUND: Interventions such as opiate substitution therapy (OST) and high-coverage needle and syringe programs (HCNSP) cannot substantially reduce hepatitis C virus (HCV) prevalence among people who inject drugs (PWID). HCV antiviral treatment may prevent onward transmission. We project the impact of combining OST, HCNSP, and antiviral treatment on HCV prevalence/incidence among PWID. METHODS: An HCV transmission model among PWID was used to project the combinations of OST, HCNSP, and antiviral treatment required to achieve different prevalence and incidence reductions within 10 years for 3 chronic prevalence scenarios and the impact of HCV treatment if only delivered through OST programs. Multivariate and univariate sensitivity analyses were performed. RESULTS: Large reductions (>45%) in HCV chronic prevalence over 10 years require HCV antiviral treatment. Scaling up OST and HCNSP substantially reduces the treatment rate required to achieve specific HCV prevalence reductions. If OST and HCNSP coverage were increased to 40% each (no coverage at baseline), then annually treating 10, 23, or 42 per 1000 PWID over 10 years would halve prevalence for 20%, 40%, or 60% baseline chronic HCV prevalences, respectively. Approximately 30% fewer treatments are necessary with new direct-acting antivirals. If coverage of OST and HCNSP is 50% at baseline, similar prevalence reductions require higher treatment rates for the same OST and HCNSP coverage. CONCLUSIONS: Combining antiviral treatment with OST with HCNSP is critical for achieving substantial reductions (>50%) in HCV chronic prevalence over 10 years. Empirical studies are required on how best to scale up antiviral treatment and combine treatment with other interventions.
Refs biblio. :	30
Affiliation :	School of Social and Community Medicine, University of Bristol, UK
Lien :	http://dx.doi.org/10.1093/cid/cit296
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74550

[article] Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy [Périodique] / N. K. MARTIN ; M. HICKMAN ; S. J. HUTCHINSON ; D. J. GOLDBERG ; P. VICKERMAN . - 2013 . - S39-S45.
Langues : Anglais
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S39-S45

Mots-clés :	Thésaurus Géographique ROYAUME-UNI Thésaurus TOXIBASE HEPATITE ; INTERVENTION ; USAGER ; REDUCTION DES RISQUES ; MODELE ; TRAITEMENT DE MAINTENANCE ; ECHANGE DE SERINGUES ; ANTIVIRAUX ; PREVALENCE
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	BACKGROUND: Interventions such as opiate substitution therapy (OST) and high-coverage needle and syringe programs (HCNSP) cannot substantially reduce hepatitis C virus (HCV) prevalence among people who inject drugs (PWID). HCV antiviral treatment may prevent onward transmission. We project the impact of combining OST, HCNSP, and antiviral treatment on HCV prevalence/incidence among PWID. METHODS: An HCV transmission model among PWID was used to project the combinations of OST, HCNSP, and antiviral treatment required to achieve different prevalence and incidence reductions within 10 years for 3 chronic prevalence scenarios and the impact of HCV treatment if only delivered through OST programs. Multivariate and univariate sensitivity analyses were performed. RESULTS: Large reductions (>45%) in HCV chronic prevalence over 10 years require HCV antiviral treatment. Scaling up OST and HCNSP substantially reduces the treatment rate required to achieve specific HCV prevalence reductions. If OST and HCNSP coverage were increased to 40% each (no coverage at baseline), then annually treating 10, 23, or 42 per 1000 PWID over 10 years would halve prevalence for 20%, 40%, or 60% baseline chronic HCV prevalences, respectively. Approximately 30% fewer treatments are necessary with new direct-acting antivirals. If coverage of OST and HCNSP is 50% at baseline, similar prevalence reductions require higher treatment rates for the same OST and HCNSP coverage. CONCLUSIONS: Combining antiviral treatment with OST with HCNSP is critical for achieving substantial reductions (>50%) in HCV chronic prevalence over 10 years. Empirical studies are required on how best to scale up antiviral treatment and combine treatment with other interventions.
Refs biblio. :	30
Affiliation :	School of Social and Community Medicine, University of Bristol, UK
Lien :	http://dx.doi.org/10.1093/cid/cit296
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74550

[article] 
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S56-S61

Titre :	Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all
Type de document :	Périodique
Auteurs :	P. BRUGGMANN ; A. H. LITWIN
Année de publication :	2013
Article en page(s) :	S56-S61
Langues :	Anglais
Mots-clés :	Thésaurus TOXIBASE HEPATITE ; MODELE ; PRISE EN CHARGE ; USAGER ; TRAITEMENT INTEGRE ; INJECTION ; MEDECIN GENERALISTE
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	One of the major obstacles to hepatitis C virus (HCV) care in people who inject drugs (PWID) is the lack of treatment settings that are suitably adapted for the needs of this vulnerable population. Nevertheless, HCV treatment has been delivered successfully to PWID through various multidisciplinary models such as community-based clinics, substance abuse treatment clinics, and specialized hospital-based clinics. Models may be integrated in primary care - all under one roof in either addiction care units or general practitioner-based models - or can occur in secondary or tertiary care settings. Additional innovative models include directly observed therapy and peer-based models. A high level of acceptance of the individual life circumstances of PWID rather than rigid exclusion criteria will determine the level of success of any model of HCV management. The impact of highly potent and well-tolerated interferon-free HCV treatment regimens will remain negligible as long as access to therapy cannot be expanded to the most affected risk groups.
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	50
Affiliation :	Arud Centres for Addiction Medicine, Zurich, Switzerland
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74551

[article] Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all [Périodique] / P. BRUGGMANN ; A. H. LITWIN . - 2013 . - S56-S61.
Langues : Anglais
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S56-S61

Mots-clés :	Thésaurus TOXIBASE HEPATITE ; MODELE ; PRISE EN CHARGE ; USAGER ; TRAITEMENT INTEGRE ; INJECTION ; MEDECIN GENERALISTE
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	One of the major obstacles to hepatitis C virus (HCV) care in people who inject drugs (PWID) is the lack of treatment settings that are suitably adapted for the needs of this vulnerable population. Nevertheless, HCV treatment has been delivered successfully to PWID through various multidisciplinary models such as community-based clinics, substance abuse treatment clinics, and specialized hospital-based clinics. Models may be integrated in primary care - all under one roof in either addiction care units or general practitioner-based models - or can occur in secondary or tertiary care settings. Additional innovative models include directly observed therapy and peer-based models. A high level of acceptance of the individual life circumstances of PWID rather than rigid exclusion criteria will determine the level of success of any model of HCV management. The impact of highly potent and well-tolerated interferon-free HCV treatment regimens will remain negligible as long as access to therapy cannot be expanded to the most affected risk groups.
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	50
Affiliation :	Arud Centres for Addiction Medicine, Zurich, Switzerland
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74551

[article] 
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S62-S69

Titre :	Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study
Type de document :	Périodique
Auteurs :	M. ALAVI ; J. GREBELY ; M. MICALLEF ; A. J. DUNLOP ; A. C. BALCOMB ; C. A. DAY ; C. TRELOAR ; N. BATH ; P. S. HABER ; G. J. DORE
Année de publication :	2013
Article en page(s) :	S62-S69
Langues :	Anglais
Mots-clés :	Thésaurus Géographique AUSTRALIE Thésaurus TOXIBASE HEPATITE ; USAGER ; INFECTION ; TRAITEMENT INTEGRE ; TRAITEMENT DE MAINTENANCE ; ETUDE PROSPECTIVE ; ACCES AUX SOINS
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	BACKGROUND: Access to hepatitis C virus (HCV) treatment remains extremely limited among people who inject drugs (PWID). HCV assessment and treatment was evaluated through an innovative model for the provision of HCV care among PWID with chronic HCV infection. METHODS: Enhancing Treatment for Hepatitis C in Opioid Substitution Settings (ETHOS) was a prospective observational cohort. Recruitment was through 5 opioid substitution treatment (OST) clinics, 2 community health centers, and 1 Aboriginal community controlled health organization in New South Wales, Australia. RESULTS: Among 387 enrolled participants, mean age was 41 years, 71% were male, and 15% were of Aboriginal ethnicity. Specialist assessment was undertaken in 191 (49%) participants, and 84 (22%) commenced interferon-based treatment. In adjusted analysis, HCV specialist assessment was associated with non-Aboriginal ethnicity (adjusted odds ratio [AOR], 4.02; 95% confidence interval [CI], 2.05-7.90), no recent benzodiazepine use (AOR, 2.06; 95% CI, 1.31-3.24), and non-1 HCV genotype (AOR, 2.13; 95% CI, 1.32-3.43). In adjusted analysis, HCV treatment was associated with non-Aboriginal ethnicity (AOR, 4.59; 95% CI, 1.49-14.12), living with the support of family and/or friends (AOR, 2.15; 95% CI, 1.25-3.71), never receiving OST (AOR, 4.40; 95% CI, 2.27-8.54), no recent methamphetamine use (AOR, 2.26; 95% CI, 1.12-4.57), and non-1 HCV genotype (AOR, 3.07; 95% CI, 1.67-5.64). CONCLUSIONS: HCV treatment uptake was relatively high among this highly marginalized population of PWID. Potentially modifiable factors associated with treatment include drug use and social support.
Refs biblio. :	29
Affiliation :	The Kirby Institute, University of New South Wales, Sydney, Australia
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74552

[article] Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study [Périodique] / M. ALAVI ; J. GREBELY ; M. MICALLEF ; A. J. DUNLOP ; A. C. BALCOMB ; C. A. DAY ; C. TRELOAR ; N. BATH ; P. S. HABER ; G. J. DORE . - 2013 . - S62-S69.
Langues : Anglais
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S62-S69

Mots-clés :	Thésaurus Géographique AUSTRALIE Thésaurus TOXIBASE HEPATITE ; USAGER ; INFECTION ; TRAITEMENT INTEGRE ; TRAITEMENT DE MAINTENANCE ; ETUDE PROSPECTIVE ; ACCES AUX SOINS
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	BACKGROUND: Access to hepatitis C virus (HCV) treatment remains extremely limited among people who inject drugs (PWID). HCV assessment and treatment was evaluated through an innovative model for the provision of HCV care among PWID with chronic HCV infection. METHODS: Enhancing Treatment for Hepatitis C in Opioid Substitution Settings (ETHOS) was a prospective observational cohort. Recruitment was through 5 opioid substitution treatment (OST) clinics, 2 community health centers, and 1 Aboriginal community controlled health organization in New South Wales, Australia. RESULTS: Among 387 enrolled participants, mean age was 41 years, 71% were male, and 15% were of Aboriginal ethnicity. Specialist assessment was undertaken in 191 (49%) participants, and 84 (22%) commenced interferon-based treatment. In adjusted analysis, HCV specialist assessment was associated with non-Aboriginal ethnicity (adjusted odds ratio [AOR], 4.02; 95% confidence interval [CI], 2.05-7.90), no recent benzodiazepine use (AOR, 2.06; 95% CI, 1.31-3.24), and non-1 HCV genotype (AOR, 2.13; 95% CI, 1.32-3.43). In adjusted analysis, HCV treatment was associated with non-Aboriginal ethnicity (AOR, 4.59; 95% CI, 1.49-14.12), living with the support of family and/or friends (AOR, 2.15; 95% CI, 1.25-3.71), never receiving OST (AOR, 4.40; 95% CI, 2.27-8.54), no recent methamphetamine use (AOR, 2.26; 95% CI, 1.12-4.57), and non-1 HCV genotype (AOR, 3.07; 95% CI, 1.67-5.64). CONCLUSIONS: HCV treatment uptake was relatively high among this highly marginalized population of PWID. Potentially modifiable factors associated with treatment include drug use and social support.
Refs biblio. :	29
Affiliation :	The Kirby Institute, University of New South Wales, Sydney, Australia
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74552

[article] 
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S80-S89

Titre :	Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis
Type de document :	Périodique
Auteurs :	E. ASPINALL ; S. CORSON ; J. S. DOYLE ; J. GREBELY ; S. J. HUTCHINSON ; G. J. DORE ; D. J. GOLDBERG ; M. E. HELLARD
Année de publication :	2013
Article en page(s) :	S80-S89
Langues :	Anglais
Mots-clés :	Thésaurus TOXIBASE HEPATITE ; USAGER ; TRAITEMENT ; INJECTION ; INFECTION ; RECHUTE
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	BACKGROUND: Although guidelines recommend that people who inject drugs (PWID) should not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat PWID. The aim of this review was to investigate sustained virologic response (SVR), adherence, discontinuation, and HCV reinfection among PWID. METHODS: A search of Medline, Embase, and Cochrane databases (between 2002 and January 2012) was conducted for primary articles/conference abstracts examining HCV treatment outcomes in PWID. Meta-analysis was used to obtain pooled estimates of SVR, adherence, discontinuation, and HCV reinfection. RESULTS: Ten primary articles and 1 conference abstract met the inclusion criteria. Across 6 studies (comprising 314 drug users, of whom 141 [45%] were PWID), pooled SVR was 56% (95% confidence interval [CI], 50%-61%) for all genotypes, 37% (95% CI, 26%-48%) for genotypes 1/4, and 67% (95% CI, 56%-78%) for genotypes 2/3. Pooled 80/80/80 adherence was 82% (95% CI, 74%-89%) across 2 studies, and pooled treatment discontinuation was 22% (95% CI, 16%-27%) across 4 studies. Across 5 studies (comprising 131 drug users) examining reinfection, pooled risk was 2.4 (95% CI, .9-6.1) per 100 person-years. CONCLUSIONS: HCV treatment outcomes are acceptable in PWID, supporting treatment guidelines. The pooled estimate of HCV reinfection risk was low, but there was considerable uncertainty around this estimate. Further studies on the risk of reinfection are needed to assess the long-term effectiveness of HCV treatment in PWID.
Sous-type de document :	Méta-analyse / Meta-analysis ; Revue de la littérature / Literature review
Refs biblio. :	30
Affiliation :	Health Protection Scotland, National Services Scotland, Glasgow, Scotland, UK
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74553

[article] Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis [Périodique] / E. ASPINALL ; S. CORSON ; J. S. DOYLE ; J. GREBELY ; S. J. HUTCHINSON ; G. J. DORE ; D. J. GOLDBERG ; M. E. HELLARD . - 2013 . - S80-S89.
Langues : Anglais
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S80-S89

Mots-clés :	Thésaurus TOXIBASE HEPATITE ; USAGER ; TRAITEMENT ; INJECTION ; INFECTION ; RECHUTE
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	BACKGROUND: Although guidelines recommend that people who inject drugs (PWID) should not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat PWID. The aim of this review was to investigate sustained virologic response (SVR), adherence, discontinuation, and HCV reinfection among PWID. METHODS: A search of Medline, Embase, and Cochrane databases (between 2002 and January 2012) was conducted for primary articles/conference abstracts examining HCV treatment outcomes in PWID. Meta-analysis was used to obtain pooled estimates of SVR, adherence, discontinuation, and HCV reinfection. RESULTS: Ten primary articles and 1 conference abstract met the inclusion criteria. Across 6 studies (comprising 314 drug users, of whom 141 [45%] were PWID), pooled SVR was 56% (95% confidence interval [CI], 50%-61%) for all genotypes, 37% (95% CI, 26%-48%) for genotypes 1/4, and 67% (95% CI, 56%-78%) for genotypes 2/3. Pooled 80/80/80 adherence was 82% (95% CI, 74%-89%) across 2 studies, and pooled treatment discontinuation was 22% (95% CI, 16%-27%) across 4 studies. Across 5 studies (comprising 131 drug users) examining reinfection, pooled risk was 2.4 (95% CI, .9-6.1) per 100 person-years. CONCLUSIONS: HCV treatment outcomes are acceptable in PWID, supporting treatment guidelines. The pooled estimate of HCV reinfection risk was low, but there was considerable uncertainty around this estimate. Further studies on the risk of reinfection are needed to assess the long-term effectiveness of HCV treatment in PWID.
Sous-type de document :	Méta-analyse / Meta-analysis ; Revue de la littérature / Literature review
Refs biblio. :	30
Affiliation :	Health Protection Scotland, National Services Scotland, Glasgow, Scotland, UK
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74553

[article] 
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S105-S110

Titre :	Hepatitis C virus reinfection following treatment among people who use drugs
Type de document :	Périodique
Auteurs :	B. P. GRADY ; J. SCHINKEL ; X. V. THOMAS ; O. DALGARD
Année de publication :	2013
Article en page(s) :	S105-S110
Langues :	Anglais
Mots-clés :	Thésaurus TOXIBASE HEPATITE ; INFECTION ; USAGER ; RECHUTE ; VIRUS ; SYSTEME IMMUNITAIRE
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	Most new cases of hepatitis C virus (HCV) infections in the developed world are associated with injection drug use. However, treatment for people who inject drugs (PWID) is controversial, as successful treatment risks being followed by new infection. Reinfection after sustained virologic response has been reported, but is the risk so great that treatment should be withheld from this large HCV population? Preliminary evidence suggests that the reinfection incidence is low, but studies to date have been limited by small sample size and few cases of reinfection. In this review, we assess data from studies among PWID of HCV reinfection following treatment to give a reasonable estimate on how frequently reinfection appears and try to characterize those most at risk, The observation that spontaneous clearance of HCV reinfection following treatment occurs is suggestive of a partial protective immunity against persistent infection.
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	39
Affiliation :	Department of Infectious Diseases, Akershus University Hospital, Oslo, Norway
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74554

[article] Hepatitis C virus reinfection following treatment among people who use drugs [Périodique] / B. P. GRADY ; J. SCHINKEL ; X. V. THOMAS ; O. DALGARD . - 2013 . - S105-S110.
Langues : Anglais
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S105-S110

Mots-clés :	Thésaurus TOXIBASE HEPATITE ; INFECTION ; USAGER ; RECHUTE ; VIRUS ; SYSTEME IMMUNITAIRE
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	Most new cases of hepatitis C virus (HCV) infections in the developed world are associated with injection drug use. However, treatment for people who inject drugs (PWID) is controversial, as successful treatment risks being followed by new infection. Reinfection after sustained virologic response has been reported, but is the risk so great that treatment should be withheld from this large HCV population? Preliminary evidence suggests that the reinfection incidence is low, but studies to date have been limited by small sample size and few cases of reinfection. In this review, we assess data from studies among PWID of HCV reinfection following treatment to give a reasonable estimate on how frequently reinfection appears and try to characterize those most at risk, The observation that spontaneous clearance of HCV reinfection following treatment occurs is suggestive of a partial protective immunity against persistent infection.
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	39
Affiliation :	Department of Infectious Diseases, Akershus University Hospital, Oslo, Norway
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74554

[article] 
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S125-S128

Titre :	Drug-drug interactions in the treatment of HCV among people who inject drugs
Type de document :	Périodique
Auteurs :	S. MAUSS ; H. KLINKER
Année de publication :	2013
Article en page(s) :	S125-S128
Langues :	Anglais
Mots-clés :	Thésaurus TOXIBASE HEPATITE ; TRAITEMENT ; ANTIVIRAUX ; INTERACTION CHIMIQUE ; USAGER ; PHARMACOLOGIE ; PSYCHOTROPES
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	Boceprevir and telaprevir are inhibitors and substrates of the cytochrome P450 3A4 family. With the use of these HCV protease inhibitors as part of standard therapy for chronic hepatitis C genotype 1 infection, drug-drug interactions with multiple medications being inductors, inhibitors, or substrates of cytochrome P450 3A4 can be expected. Due to the complexity of these interactions, predicting the expected magnitude and sometimes even the direction of the effect has proven to be difficult. Pharmacokinetic studies should be carried out to evaluate drugs with clinical relevance and possible interactions. This review focuses on the data available regarding drugs that are frequently used in the setting of addiction or used by patients with addiction. In addition to highlighting relevant drug-drug interactions, alternative drugs that can be safely used are suggested.
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	25
Affiliation :	Center for HIV and Hepatogastroenterology, Düsseldorf, Germany
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74555

[article] Drug-drug interactions in the treatment of HCV among people who inject drugs [Périodique] / S. MAUSS ; H. KLINKER . - 2013 . - S125-S128.
Langues : Anglais
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S125-S128

Mots-clés :	Thésaurus TOXIBASE HEPATITE ; TRAITEMENT ; ANTIVIRAUX ; INTERACTION CHIMIQUE ; USAGER ; PHARMACOLOGIE ; PSYCHOTROPES
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	Boceprevir and telaprevir are inhibitors and substrates of the cytochrome P450 3A4 family. With the use of these HCV protease inhibitors as part of standard therapy for chronic hepatitis C genotype 1 infection, drug-drug interactions with multiple medications being inductors, inhibitors, or substrates of cytochrome P450 3A4 can be expected. Due to the complexity of these interactions, predicting the expected magnitude and sometimes even the direction of the effect has proven to be difficult. Pharmacokinetic studies should be carried out to evaluate drugs with clinical relevance and possible interactions. This review focuses on the data available regarding drugs that are frequently used in the setting of addiction or used by patients with addiction. In addition to highlighting relevant drug-drug interactions, alternative drugs that can be safely used are suggested.
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	25
Affiliation :	Center for HIV and Hepatogastroenterology, Düsseldorf, Germany
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74555

[article] 
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S129-S137

Titre :	Recommendations for the management of hepatitis C virus infection among people who inject drugs
Type de document :	Périodique
Auteurs :	G. ROBAEYS ; J. GREBELY ; S. MAUSS ; P. BRUGGMANN ; J. MOUSSALLI ; A. DE GOTTARDI ; T. SWAN ; A. ARAIN ; A. KAUTZ ; H. STÖVER ; H. WEDEMEYER ; M. SCHAEFER ; L. TAYLOR ; M. BACKMUND ; O. DALGARD ; M. PRINS ; G. J. DORE
Année de publication :	2013
Article en page(s) :	S129-S137
Langues :	Anglais
Mots-clés :	Thésaurus TOXIBASE HEPATITE ; RECOMMANDATION ; PRISE EN CHARGE ; INFECTION ; USAGER ; INJECTION ; TRAITEMENT
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	In the developed world, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). The burden of HCV-related liver disease in this group is increasing, but treatment uptake among PWID remains low. Among PWID, there are a number of barriers to care that should be considered and systematically addressed, but these barriers should not exclude PWID from HCV treatment. Furthermore, it has been clearly demonstrated that HCV treatment is safe and effective across a broad range of multidisciplinary healthcare settings. Given the burden of HCV-related disease among PWID, strategies to enhance HCV assessment and treatment in this group are urgently needed. These recommendations demonstrate that treatment among PWID is feasible and provides a framework for HCV assessment, management, and treatment. Further research is needed to evaluate strategies to enhance assessment, adherence, and SVR among PWID, particularly as new treatments for HCV infection become available.
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	130
Affiliation :	Department of Gastroenterology and Hepatology, Ziekenhuis Oost Limburg, Genk, Belgium
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74556

[article] Recommendations for the management of hepatitis C virus infection among people who inject drugs [Périodique] / G. ROBAEYS ; J. GREBELY ; S. MAUSS ; P. BRUGGMANN ; J. MOUSSALLI ; A. DE GOTTARDI ; T. SWAN ; A. ARAIN ; A. KAUTZ ; H. STÖVER ; H. WEDEMEYER ; M. SCHAEFER ; L. TAYLOR ; M. BACKMUND ; O. DALGARD ; M. PRINS ; G. J. DORE . - 2013 . - S129-S137.
Langues : Anglais
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S129-S137

Mots-clés :	Thésaurus TOXIBASE HEPATITE ; RECOMMANDATION ; PRISE EN CHARGE ; INFECTION ; USAGER ; INJECTION ; TRAITEMENT
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	In the developed world, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). The burden of HCV-related liver disease in this group is increasing, but treatment uptake among PWID remains low. Among PWID, there are a number of barriers to care that should be considered and systematically addressed, but these barriers should not exclude PWID from HCV treatment. Furthermore, it has been clearly demonstrated that HCV treatment is safe and effective across a broad range of multidisciplinary healthcare settings. Given the burden of HCV-related disease among PWID, strategies to enhance HCV assessment and treatment in this group are urgently needed. These recommendations demonstrate that treatment among PWID is feasible and provides a framework for HCV assessment, management, and treatment. Further research is needed to evaluate strategies to enhance assessment, adherence, and SVR among PWID, particularly as new treatments for HCV infection become available.
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	130
Affiliation :	Department of Gastroenterology and Hepatology, Ziekenhuis Oost Limburg, Genk, Belgium
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=74556

[article] 
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S75-S79

Titre :	Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection
Type de document :	Périodique
Auteurs :	S. CRAWFORD ; N. BATH
Année de publication :	2013
Article en page(s) :	S75-S79
Langues :	Anglais
Mots-clés :	Thésaurus TOXIBASE HEPATITE ; TRAITEMENT DE MAINTENANCE ; USAGER ; PAIR ; MODELE ; INJECTION ; PARTENARIAT ; TRAITEMENT ; FORMATION
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	People who inject drugs (PWID) are the group most affected by HCV; however, treatment uptake has been low. Engagement between PWID and healthcare workers has been characterized by mistrust and discrimination. Peer support for HCV is one way to overcome these barriers. Peer support models for chronic disease management have been successfully applied for other diseases. HCV peer support models have been implemented in various settings, but those that include opioid substitution treatment have been more common. Most models have been either service generated (provider led) or community controlled (peer led). Peer support models have been implemented successfully, with a range of outcomes including increased treatment knowledge and uptake and improved service provision. Genuine partnerships between peers and services were common across models and led to positive transformations for both clients and services. Further investigation of peer support for HCV treatment and its impact on both individuals and services is recommended.
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	26
Affiliation :	New South Wales Users and AIDS Association, Sydney, Australia
Lien :	http://dx.doi.org/10.1093/cid/cit297
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=78441

[article] Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection [Périodique] / S. CRAWFORD ; N. BATH . - 2013 . - S75-S79.
Langues : Anglais
in Clinical Infectious Diseases > Vol.57, Suppl.2 (August 2013) . - S75-S79

Mots-clés :	Thésaurus TOXIBASE HEPATITE ; TRAITEMENT DE MAINTENANCE ; USAGER ; PAIR ; MODELE ; INJECTION ; PARTENARIAT ; TRAITEMENT ; FORMATION
Discipline :	MAL Maladies infectieuses / Infectious diseases
Domaine :	Drogues illicites / Illicit drugs
Résumé :	People who inject drugs (PWID) are the group most affected by HCV; however, treatment uptake has been low. Engagement between PWID and healthcare workers has been characterized by mistrust and discrimination. Peer support for HCV is one way to overcome these barriers. Peer support models for chronic disease management have been successfully applied for other diseases. HCV peer support models have been implemented in various settings, but those that include opioid substitution treatment have been more common. Most models have been either service generated (provider led) or community controlled (peer led). Peer support models have been implemented successfully, with a range of outcomes including increased treatment knowledge and uptake and improved service provision. Genuine partnerships between peers and services were common across models and led to positive transformations for both clients and services. Further investigation of peer support for HCV treatment and its impact on both individuals and services is recommended.
Sous-type de document :	Revue de la littérature / Literature review
Refs biblio. :	26
Affiliation :	New South Wales Users and AIDS Association, Sydney, Australia
Lien :	http://dx.doi.org/10.1093/cid/cit297
Permalink :	https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=78441